239 related articles for article (PubMed ID: 37181145)
1. Virosome: An engineered virus for vaccine delivery.
Ali H; Akbar M; Iqbal B; Ali F; Sharma NK; Kumar N; Najmi A; Albratty M; Alhazmi HA; Madkhali OA; Zoghebi K; Alam MS
Saudi Pharm J; 2023 May; 31(5):752-764. PubMed ID: 37181145
[No Abstract] [Full Text] [Related]
2. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
[TBL] [Abstract][Full Text] [Related]
3. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.
Felnerova D; Viret JF; Glück R; Moser C
Curr Opin Biotechnol; 2004 Dec; 15(6):518-29. PubMed ID: 15560978
[TBL] [Abstract][Full Text] [Related]
4. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
5. Influenza virosomes as a vaccine adjuvant and carrier system.
Moser C; Amacker M; Zurbriggen R
Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
[TBL] [Abstract][Full Text] [Related]
6. Liposomes as vaccine delivery systems: a review of the recent advances.
Schwendener RA
Ther Adv Vaccines; 2014 Nov; 2(6):159-82. PubMed ID: 25364509
[TBL] [Abstract][Full Text] [Related]
7. The virosome concept for influenza vaccines.
Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
[TBL] [Abstract][Full Text] [Related]
8. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment.
Liu H; Tu Z; Feng F; Shi H; Chen K; Xu X
Acta Pharm; 2015 Jun; 65(2):105-16. PubMed ID: 26011928
[TBL] [Abstract][Full Text] [Related]
9. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
Glück R; Moser C; Metcalfe IC
Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
[TBL] [Abstract][Full Text] [Related]
10. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
[TBL] [Abstract][Full Text] [Related]
11. Applications of influenza virosomes as a delivery system.
Cusi MG
Hum Vaccin; 2006; 2(1):1-7. PubMed ID: 17012895
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and antigen delivery properties of virosomes.
Glück R; Burri KG; Metcalfe I
Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems.
Glück R; Metcalfe IC
Vaccine; 2003 Jan; 21(7-8):611-5. PubMed ID: 12531327
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.
Shafique M; Meijerhof T; Wilschut J; de Haan A
PLoS One; 2013; 8(4):e61287. PubMed ID: 23593453
[TBL] [Abstract][Full Text] [Related]
15. Influenza virosomes in vaccine development.
Huckriede A; Bungener L; Daemen T; Wilschut J
Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
[TBL] [Abstract][Full Text] [Related]
16. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
17. Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.
Asadi K; Gholami A
Int J Biol Macromol; 2021 Jul; 182():648-658. PubMed ID: 33862071
[TBL] [Abstract][Full Text] [Related]
18. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
[TBL] [Abstract][Full Text] [Related]
19. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Virosome vs. Liposome as drug delivery vehicle using HepG2 and CaCo2 cell lines.
Kumar V; Kumar R; Jain VK; Nagpal S
J Microencapsul; 2021 Aug; 38(5):263-275. PubMed ID: 33719838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
